DLGAP5 has been reported to be correlated with clinical prognosis, immune cell infiltration, and tumor mutational burden across multiple tumors in previous studies [30]; thus, BUB1B was chosen for further analysis. This evidence concerns the gene BUB1B and neoplasm.